AR121522A1 - ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) - Google Patents

ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)

Info

Publication number
AR121522A1
AR121522A1 ARP210100584A ARP210100584A AR121522A1 AR 121522 A1 AR121522 A1 AR 121522A1 AR P210100584 A ARP210100584 A AR P210100584A AR P210100584 A ARP210100584 A AR P210100584A AR 121522 A1 AR121522 A1 AR 121522A1
Authority
AR
Argentina
Prior art keywords
sars2
cov
antibodies
covid
antibodies against
Prior art date
Application number
ARP210100584A
Other languages
English (en)
Inventor
Franklin Gerardus Grosveld
Dubravka Drabek
Haperen Rien Van
Berend Jan Bosch
Juliette Fedry
Daniel L Hurdiss
Thijs Kuiken
Bartholomeus Leonardus Haagmans
Barry Hubertus Gerardus Rockx
Original Assignee
Harbour Antibodies Bv
Univ Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbour Antibodies Bv, Univ Utrecht Holding Bv filed Critical Harbour Antibodies Bv
Publication of AR121522A1 publication Critical patent/AR121522A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos y fragmentos de unión al antígeno de los mismos que reconocen proteínas de la espícula de SARS-Cov-2 (SARS2-S). En algunas formas de realización, los anticuerpos se unen a SARS2-S con una gran afinidad y/o inhiben una infección por SARS-Cov-2 en células humanas. En algunas formas de realización, los anticuerpos proveen un medio para prevenir, tratar o mejorar una infección por SARS2. En algunas formas de realización, los anticuerpos se usan en ensayos de diagnóstico (por ejemplo, ensayos de serodiagnóstico para SARS2).
ARP210100584A 2020-03-12 2021-03-05 ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19) AR121522A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2003632.3A GB202003632D0 (en) 2020-03-12 2020-03-12 SARS-Cov-2 (SARS2, COVID-19) antibodies

Publications (1)

Publication Number Publication Date
AR121522A1 true AR121522A1 (es) 2022-06-08

Family

ID=70453696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100584A AR121522A1 (es) 2020-03-12 2021-03-05 ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)

Country Status (6)

Country Link
US (2) US20210340225A1 (es)
AR (1) AR121522A1 (es)
GB (5) GB202003632D0 (es)
TW (1) TW202200612A (es)
UY (1) UY39118A (es)
WO (2) WO2021180604A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN113583114B (zh) * 2020-04-30 2023-09-26 养生堂有限公司 针对SARS-CoV-2的抗体及其用途
CN116075315A (zh) 2020-05-08 2023-05-05 刘扶东 嵌合流感疫苗
US20230220053A1 (en) * 2020-05-18 2023-07-13 Elpis Biopharmaceuticals ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
CN111518203B (zh) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) 用于新型冠状病毒检测的试剂盒
CN112898415B (zh) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种检测新型冠状病毒的抗体及检测试剂盒
CN112979793B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 检测新型冠状病毒的抗体
CN112898416B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 新型冠状病毒np蛋白的结合蛋白及其应用
CN111518202B (zh) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) 新型冠状病毒抗体和新型冠状病毒抗体的elisa检测试剂盒
CN112979790B (zh) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗体及在检测新型冠状病毒中的用途
CN112979791B (zh) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的抗体
WO2021247779A1 (en) 2020-06-03 2021-12-09 Regeneron Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES
CN113831409B (zh) * 2020-06-08 2023-04-25 中国科学院深圳先进技术研究院 一种抗sar-cov-2抗体或其抗原结合片段及其应用
CN113896788B (zh) * 2020-06-22 2023-05-23 中国科学院深圳先进技术研究院 抗sar-cov-2（covid-19）全人源单克隆抗体及其制法与应用
CN113480644B (zh) * 2020-08-10 2022-09-16 南开大学 一种抗冠状病毒的抗体及其应用
CN114920832B (zh) * 2020-08-19 2023-10-13 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN115304671B (zh) * 2020-08-19 2023-10-17 重庆医科大学 新冠病毒rbd特异性单克隆抗体及其应用
CN118206645A (zh) * 2020-08-19 2024-06-18 重庆医科大学 新型冠状病毒rbd特异性单克隆抗体和应用
CN114933650A (zh) * 2020-08-19 2022-08-23 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN115925899A (zh) * 2020-08-19 2023-04-07 重庆医科大学 新型冠状病毒rbd特异性单克隆抗体和应用
WO2022101839A1 (en) * 2020-11-12 2022-05-19 Cadila Healthcare Limited Anti-sars-cov-2 monoclonal antibodies and cocktail thereof
US11693011B2 (en) * 2020-12-14 2023-07-04 Inbios International, Inc. Neutralizing antibody immunoassays
WO2022271884A2 (en) * 2021-06-22 2022-12-29 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes
WO2023048656A2 (en) * 2021-09-24 2023-03-30 Chulalongkorn University Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
JP2024536380A (ja) * 2021-10-07 2024-10-04 セキラス ピーティーワイ リミテッド 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ
WO2023184280A1 (zh) * 2022-03-30 2023-10-05 上海科技大学 一种抗新冠纳米抗体及其应用
WO2024007013A2 (en) * 2022-06-30 2024-01-04 Modex Therapeutics, Inc. Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20110159001A1 (en) * 2008-01-17 2011-06-30 Institute For Research In Biomedicine CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP4356927A3 (en) * 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2021180604A1 (en) 2021-09-16
UY39118A (es) 2021-10-29
GB202013024D0 (en) 2020-10-07
TW202200612A (zh) 2022-01-01
WO2021180602A1 (en) 2021-09-16
US20210340225A1 (en) 2021-11-04
US20220017606A1 (en) 2022-01-20
GB202003632D0 (en) 2020-04-29
GB202015240D0 (en) 2020-11-11
GB202101720D0 (en) 2021-03-24
GB202004340D0 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
UY39118A (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2023000705A1 (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CL2020003422A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
BR112019000431A2 (pt) anticorpos contra tim3 e usos dos mesmos
BR112018067458A2 (pt) anticorpos para tigit
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
AR083293A1 (es) Agentes de union a cd33
CL2022000368A1 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
AR122111A1 (es) ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS
CO7061040A2 (es) Anticuerpos contra la metaloproteinasa de la matriz 9
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
DOP2021000145A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
CO2021000497A2 (es) Proteína de unión al antígeno anti-steap1
CO2023002034A2 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
CL2024000091A1 (es) Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2
CO2023009279A2 (es) Moléculas de unión a gucy2c y sus usos
CL2022000052A1 (es) Anticuerpos de pre–direccionamiento y metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure